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Abstract Introduction: The aim of this study was to (1) replicate previous associations between six blood lipids
and Alzheimer’s disease (AD) (Proitsi et al 2015) and (2) identify novel associations between lipids, clin-
ical AD diagnosis, disease progression and brain atrophy (left/right hippocampus/entorhinal cortex).
Methods: We performed untargeted lipidomic analysis on 148 AD and 152 elderly control plasma
samples and used univariate and multivariate analysis methods.
Results: We replicated our previous lipids associations and reported novel associations between
lipids molecules and all phenotypes. A combination of 24 molecules classified AD patients with
.70% accuracy in a test and a validation data set, and we identified lipid signatures that predicted
disease progression (R2 5 0.10, test data set) and brain atrophy (R2  0.14, all test data sets except
left entorhinal cortex). We putatively identified a number of metabolic features including cholesteryl
esters/triglycerides and phosphatidylcholines.
Discussion: Blood lipids are promising AD biomarkers that may lead to new treatment strategies.
 2016TheAuthors.PublishedbyElsevier Inc. onbehalf of theAlzheimer’sAssociation.This is anopen
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Alzheimer’s disease; Dementia; Brain atrophy; sMRI; Rate of cognitive decline; Lipidomics; Metabolomics;
Biomarkers; Machine learning; Multivariate; Classification; Random forest
1. Background
Alzheimer’s disease (AD) is a devastating illness and
one of the major public health challenges of the 21st
century. The lack of effective treatments and early diag-
nosis highlights the importance of the identification of
noninvasive biomarkers, for early diagnosis and disease
progression. Blood metabolites have recently emerged
as promising AD biomarkers [1–4]. They are small
molecules which could theoretically cross the already
compromised AD blood-brain barrier [5]; they are easily
accessible, and they represent an essential aspect of the
phenotype of an organism and a molecular “fingerprint”
of disease progression [6,7]. They can therefore aid early
diagnosis, recruitment into trials and may help identify
new therapeutic targets.
1These authors contributed equally to the manuscript.
2These senior authors contributed equally to the manuscript.
*CorrespondingQ3 author. Tel.:---; Fax:---.
E-mail address: petroula.proitsi@kcl.ac.uk
http://dx.doi.org/10.1016/j.jalz.2016.08.003
1552-5260/ 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A number of blood metabolomic studies have highlighted
the role of lipid compounds, such as phosphatidylcholines
(PCs) in AD [1–4]. We previously identified three PCs that
were diminished in mild cognitive impairment (MCI)
individuals and AD patients [4] and were further associated
with poorer memory performance and decreased brain func-
tion during aging [8]. We further performed lipidomics anal-
ysis and identified 10 metabolites that predicted AD in an
unseen test data set with 79% accuracy [9]; six analytes
were putatively identified as cholesteryl esters (ChoEs),
molecules related to PCs, and were reduced in MCI and AD.
Here, we performed lipidomics analysis in a sample of
142 AD patients and 135 healthy controls aiming to (1) repli-
cate our previous associations [9] and (2) discover new lipids
and combinations of lipids associated with clinical AD diag-
nosis and AD endophenotypes, such as the rate of cognitive
decline and brain atrophy measures. This is to our knowl-
edge the most comprehensive blood lipidomics study to
date to identify lipid signatures associated with AD and
AD endophenotypes, improving our current knowledge of
molecules associated with AD.
2. Methods
2.1. Patient sample collection
This study used 148 AD patients and 152 controls from the
Dementia Case Register at King’s College London and the
EU-funded AddNeuroMed study [10]. All individuals with
AD patients met criteria for either probable (NINCDS-
ADRDA, DSM-IV) or definite (CERAD) AD. All nonpopu-
lation individuals who were controls were screened for
dementia using the MMSE or ADAS-cog or were determined
to be free from dementia at neuropathologic examination or
had a Braak score 2.5. Diagnosis was confirmed by patho-
logic examination for a proportion of cases and cognitively
normal elderly controls. All AD cases had an age of onset
60 years, and controls were60 years at examination. A to-
tal of 102 AD cases and 104 controls had HDL-c, LDL-c, TC,
and TG serum levels (mmol/L) available. Nonoverlapping in-
dividuals from these cohorts have been previously reported
[9]. Each individual was required to fast for 2 hours before
sample collection, and 10 mL of blood was collected in tubes
coated with sodium ethylenediaminetetraacetic acid to pre-
vent clotting. Whole blood was centrifuged at 2000 g for
10 minutes at 4C to separate plasma, which was removed
and stored at 280C. All samples were centrifuged within
approximately 2 hours of collection.
2.2. Lipidomics
Sample treatment has been described elsewhere [4,9,11]
and is explained in detail in Supplementary Methods 1.
Briefly, 20 mL of plasma was added to a glass HPLC vial
containing a 400-ml glass insert (Chromacol, UK). Ten mi-
croliters of high purity water and 40 mL of MS grade meth-
anol were added to each sample, followed by a 2-minute
vortex mix to precipitate proteins; 200 mL of Methyl tert-
Butyl Ether (MTBE) containing 10 mg/mL of internal
standard Tripentadecanoin (TG45:0) was added, and the
samples were mixed via vortex at room temperature for
1 hour. After addition of 50 mL of high purity water, a final
sample mixing was performed before centrifugation at
3000 g for 10 minutes. The upper, lipid-containing,
MTBE phase was then injected onto the LC-MS system
directly from the vial by adjustment of the instrument nee-
dle height (17.5 mm from bottom).
Lipidomics was performed by a Waters ACQUITY
UPLC and XEVOQTOF system. The method has previously
been published [4,12] and has been shown to quantitate
.4500 metabolite species (Supplementary Methods 1).
Samples were analyzed in a randomized order, in four
batches, with pooled plasma sampled (QC) at regular inter-
vals throughout the run (n 5 30 for both positive and nega-
tive ionization). Features were extracted from netCDF
files using the R package “XCMS” [13] which performed
filtration, peak identification, matching of peaks across sam-
ples, and retention time correction. Positive and negative
ionization mode data were extracted separately and quantile
normalized.
2.3. Structural magnetic resonance imaging
Volumes of whole brain and the hippocampi and entorhi-
nal cortices were obtained using FreeSurfer 5.1.0 from 123
subjects (53 AD patients and 70 Controls) who had under-
gone sMRI. Regions were normalized by intracranial vol-
ume [14]. The volumetric data were not used to aid in the
clinical diagnosis of AD. Detailed information regarding
data acquisition, pre-processing, and quality control assess-
ment has been described elsewhere [15,16]. Before analyses,
sMRI measures were standardized to have a mean of 0 and a
standard deviation (SD) of 1.
2.4. Calculation of rate of cognitive decline
The ROD was available for 118 AD patients with analyte
data and has been described elsewhere [17]. The ROD was
based on longitudinal mini mental state examination
(MMSE) assessments [18], and only samples with at least
three MMSE measures were included in the calculation us-
ing linear mixed effect models. After covariate adjustment
[17], the slope coefficient for each sample was used as the
ROD defined as the change in MMSE per day.
2.5. Statistical analysis
2.5.1. Quality control
Data QC has been previously described [9] and included
filtering of features and individuals, data transformation,
batch effect correction, outlier detection, and imputation
(Supplementary Methods 2.1 and Supplementary
Figure 1). All analyses took place in R.3.01.
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2.5.2. Single-analyte statistical analysis
Logistic regression investigated the association of each
metabolite with clinical AD diagnosis and linear regression
the association with cognitive decline and sMRI measures.
Logistic regression and linear regression models for the
sMRI measures were adjusted for age at sampling, gender,
presence of the apolipoprotein E (APOEQ4 ) ε4 allele, batch,
and study site. For the ROD models, covariate adjustment
was only applied for batch as the rest of the covariates
were included in the ROD calculation [17]. sMRI measure-
ments were not adjusted for diagnosis to allow identification
of features associated with brain atrophy caused by AD.
False discovery rate (FDR) correction (0.05) was applied
to correct for multiple testing (“fdrtool”). Secondary models
investigated whether any associations were modified by the
APOE 4 allele or by gender.
Logistic regression results (summary statistics) for the
positive ionization metabolites were combined with the re-
sults (summary statistics) from the Proitsi et al data set [9]
using inverse variance weighted fixed effect meta-analysis
(“metafor”). The published data set [9] was restricted to
576 features extracted using Mass-Lynx, and therefore, the
analysis presented here includes a large number of previ-
ously unreported molecules extracted using XCMS. All as-
sociations are reported as the change per one metabolite
standard deviation (SD).
2.5.3. Multivariate statistical analysis
A random forest (RF) classifier approach (using “rf” and
“rfe” in “CARET”) was used to develop a clinical diagnosis
classifier as previously described [9] (Supplementary
Methods 2.2). Briefly, AD cases and controls were divided
into a training data set (2/3 of the sample) matched for age,
gender, and site and an independent data set (rest 1/3 of the
sample). An RF model was built on the training data set
(100 bootstraps), and in each iteration, each variable was as-
signed a variable importance (VI) score. The summedVI ranks
provided an indication of the predictive power for each vari-
able, and the top 10% molecules were selected for RF with
recursive feature elimination (rfe; 100 bootstraps) from 250
down to two features. For each subset of predictors, the
mean bootstrap testing performance was calculated, and the
optimal number of variables was identified using “sizeToler-
ance” that picks a subset of variables that is small without
sacrificing too much performance. Subsets of variables within
2.5% and 5% of the optimum performancewere examined and
used to build final models in the complete training data, which
were tested on the test set. The final model was also tested in
the Proitsi et al data set [9] which was used as a validation data
set, after excluding metabolites in the negative ionization
mode. The area under curve (AUC) was used to test the perfor-
mance of each classifier. Receiver operator curves (ROCs)
were plotted using “ROCR”. Models including APOE ε4
and the six features in Proitsi et al [9] were also tested.
Random forest regression (RFR) models were built for
cognitive decline and sMRImeasures following the same strat-
egy as for clinical diagnosis. The data set was split randomly
into a training (2/3 of the data) and test set (1/3 of the data)
for each endophenotype such that the training and test data
sets were stratified for each endophenotype and contained
equal representation of each site. Age, gender, and APOE ε4
presence were included in the model development for the
sMRI models, and the root mean squared error (RMSE) was
used to evaluate the performance of the models.
Table 1
Sample demographics
AD (N 5 142) Controls (N 5 135)
Difference between AD patients and
controls*
Age, mean (SD) 77 (6.5) 74 (5.9) t 5 24.8 (270), P value 5 2.62! 1026
Gender (males/females) 48/87 47/95 c2 5 0.09 (1), P value 5 .761
APOE ε4 allele (absence/presence) 54/81 99/43 c2 5 23.53 (1), P value 5 1.23! 1026
MMSE, mean (SD; Range) 20.1 (4.6; 10–27) 29.2 (0.9; 27–30) t 5 22.58 (143), P value , 2.0! 10216
ROD (per year), mean (SD)y 21.46 (1.26) NA NA
Entorhinal cortex right, mean (SD)zx 0.00092 (0.0003) 0.0013 (0.0003) t 5 6.02 (99), P value 5 2.87! 1028
Entorhinal cortex left, mean (SD)zx 0.00094 (0.0002) 0.0013 (0.0004) t 5 5.26 (86), P value 5 1.58! 1026
Hippocampus right, mean (SD)zx 0.0019 (0.0004) 0.0025 (0.0003) t 5 9.06 (100), P value 5 1.3! 10214
Hippocampus left, mean (SD)zx 0.0018 (0.0004) 0.0025 (0.003) t 5 10.57 (104), P value , 2.0! 10216
Mean HDL-c (SD), mmol/Lk 1.58 (0.37) 1.55 (0.38) b 5 0.109 (SE 5 0.33), P value 5 .068
Mean LDL-c (SD), mmol/Lk 3.42 (1.01) 3.07 (0.82) b 5 0.092 (SE 5 0.15), P value 5 .529
Mean TC (SD), mmol/Lk 5.69 (1.17) 5.29 (1.01) b 5 0.209 (SE 5 0.173), P value 5 .229
Mean TG (SD), mmol/Lk 1.64 (1.04) 1.52 (0.67) b 5 0.021 (SE 5 0.146), P value 5 .885
Statins (yes/no) 38/97 34/108 c2 5 0.436 (1), P value 5 .509
Abbreviations: AD, Alzheimer’s disease; MMSE, mini-mental state examination score; ROD, rate of cognitive decline; SD, standard deviation.
*Differences in the means/frequencies of clinical/demographic variables were tested using t test t(df), x2(df) test, or linear regression analyses after adjusting
for age, gender, the APOE ε4 allele, and study site.
yRate of decline data was available for a subset of AD patients (N 5 118).
zsMRI data were available for a subset of study participants (N 5 123 [AD 5 53, controls 5 70]).
xNormalized to intracranial volume.
kSerum HDL cholesterol, LDL cholesterol, total cholesterol, and triglyceride levels were available for a subset of study participants (N 5 208 [AD 5 102,
Controls 5 106]).
FLA 5.4.0 DTD  JALZ2275_proof  28 September 2016  2:14 pm  ce
P. Proitsi et al. / Alzheimer’s & Dementia- (2016) 1-12 3
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
w
e
b
4
C
=
F
P
O
w
e
b
4
C
=
F
P
O
Fig. 1. Associations of previously reported molecules (Proitsi et al 2015) with clinical AD diagnosis in the current data set and associations of putatively annotated
molecules, selected through random forest analyses, with the respective phenotype. (A) Association of Mass 856 with clinical AD diagnosis; (B) Association of
Mass 866 with clinical AD diagnosis; (C) Association of Mass 868 with clinical AD diagnosis; (D) Association of Mass 882 with clinical AD diagnosis; (E) As-
sociation ofMass 894with clinical AD diagnosis; (F) Association ofMass 970with clinical AD diagnosis; (G) Association ofMass 882 (2) (PC 40:4) with clinical
AD diagnosis; (H) Association of Mass 948 (1) TG (57:1) with clinical AD diagnosis; (I) Association of Mass 919 (1) TG 50:2 with Hippocampus (Right); (J)
Association ofMass 943 (1) (ChoE/TG) withHippocampus Left; (K) Association ofMass 367 (sterol) with Entorhinal Cortex (Right); (L) Association ofMass 816
(1) with Entorhinal Cortex (Left); (M) Association ofMass 771 (1) PC 36:3 with the rate of cognitive decline (ROD). The P values displayed are for the univariate
regressions after adjusting for covariates. All molecules are scaled to have a mean of 0 and a standard deviation of 1.
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3. Results
A total of 2539 positive ionization and 358 negative ioni-
zation features were initially extracted from 300 individuals.
After QC, 2216 positive and 289 negative ionization features
from 277 individuals (142 AD cases and 135 controls) were
used in subsequent analyses. Of these, 53 AD patients and 70
controls had sMRI data available, and 118 AD patients had
w
e
b
4
C
=
F
P
O
w
e
b
4
C
=
F
P
O
Fig. 1. (Continued)
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ROD data available. Sample demographics are displayed in
Table 1.
3.1. Univariate analyses results
Logistic regression analyses were initially used to inves-
tigate the association of each lipid with AD. We then per-
formed fixed-effects meta-analyses between the results of
this data set and our previously published data set [9], using
fixed-effects meta-analyses. Briefly, 425 features were
associated with AD at P value ,.05 in this data set; of
these, 87 features passed correction for multiple testing at
Q value ,0.05. After meta-analysis, 377 features were
associated with AD at P value ,.05 and 125 at Q val-
ue,0.05. All six features from Proitsi et al [9] were associ-
ated with AD at Q value ,0.05 in meta-analysis (Fig. 1
(A–F) and Table 2).
Linear regression investigated the association of each
lipid with brain atrophy and the rate of cognitive decline.
A total of 266 features were associated with the ROD at P
value ,.05, but none passed multiple testing correction. A
total of 181 features were associated with right hippocampus
volume and 224 were associated with left hippocampus vol-
ume; only six features were associated with left hippocam-
pus at Q value ,0.05. Finally, 156 and 124 features were
associated with EC volume (left and right, respectively) at
P value,.05, but no associations passed correction for mul-
tiple testing. Results for all logistic and linear regression an-
alyses are provided in Supplementary Table 1.
Overall, most lipids were reduced in AD compared to
controls (54 of the 87 features associated at Q-value
,0.05 were reduced in AD). Additionally, we observed sub-
stantial overlap between features associated with clinical
AD diagnosis and brain atrophy (Supplementary Figure 2).
We further investigated whether the APOE ε4 and gender
modified the associations between lipids and clinical AD
diagnosis. APOE ε4 modified the association of 231 features
with AD, and gender modified the association of 191 fea-
tures with AD (P value ,.05); none of these associations
was significant at Q-value , 0.05. There were only 3 indi-
viduals with the ε2/ε4 genotype, and there were therefore
no differences in lipids levels between ε4 and non-ε4 carriers
after excluding ε2/ε4 individuals.
3.2. Multivariate analysis results
A RF approach was used to identify a panel of molecules
associated with clinical AD diagnosis. After an initial RF
pre-selection step on the training data set, the top 10%
lipids (250 features), in terms of their variable importance,
were selected (after 100 Bootstraps). Furthermore, random
forest with recursive feature elimination (RF-rfe) on the
training data set showed that the best training performance
was for a model with 240 features. To choose a model with
high accuracy while reducing the number of features as low
as possible, a 5% tolerance RF-rfe model (25 features) was
fitted on the whole training data set (AUC, 0.87) and clas-
sified the test data set with 73% accuracy (Supplementary
Figure 3 and Table 3). The model was then fitted on the
training data set, excluding one negative ionization mode
analyte and classified the test training data set with 74% ac-
curacy and the Proitsi et al [9] validation data set with 71%
accuracy. There was no increase in accuracy when covari-
ates and the features from Proitsi et al [9] were added to
the models (Table 3).
Random forest regressions using the same pipeline were
applied to the ROD and brain atrophy measures. After
RFR-rfe on the training data set, the lowest mean RMSE
for RODwas for a model with 40 features. The 5% tolerance
model of the lowest RMSE model (10 features) was fitted to
the whole training data set (R25 0.49) and predicted the test
data set with R2 5 0.10 (Table 4).
For right hippocampus, the lowest RMSE was with a
model with 70 features that included age. A 5% tolerance
model (12 features) was fitted to the training data set
(R2 5 0.55) and predicted the test data set with R2 5 0.15
(Table 3). For left hippocampus, the lowest training RMSE
was with 100 features that also included age. The 5% toler-
ance model (12 features) was fitted to the training data set
(R2 5 0.59) and predicted the test data set with R2 5 0.15
(Table 3). The performance of the models was almost iden-
tical when age was excluded.
For the right EC, the lowest mean training RMSE was
with 70 features; a 5% tolerance model (12 features) was
fitted to the training data set (R2 5 0.54) and predicted the
test data set with R2 5 0.14. Finally, for left EC, a model
with 90 features had the lowest RMSE, and a 5% toler-
ance model (12 features) was fitted to the training data
set (R2 5 0.42) and predicted the test data set with
R2 5 0.01 (Table 3). Results of all 2.5% models are pre-
sented in Supplementary Tables 2 and 3, and the list of
molecules included in each classifier is found in
Supplementary Table 1. The strength of association be-
tween selected features and each model is shown in
Fig. 2, and the scaled VI of each lipid after RF-RFE/
RFR-RFE for each phenotype is shown in
Supplementary Figure 4.
3.3. Lipid annotation and putative identification
We opted to annotate the top features, in terms of VI from
each model and features selected in more than one model,
using our in-house lipid database and MS/MS fragmentation
patterns [4,11,12]. These features were annotated as mainly
LCTs and ChoEs, some were PCs and a sterol. Fig. 1
(G–M) and Table 2 present the univariate associations of these
molecules with the respective phenotypes. The association of
the annotated molecules with all phenotypes is shown in
Supplementary Figure 5. The raw intensity counts for each
AD associated lipid across AD and controls, along with the
coefficients of variation (relative standard deviation [RSD])
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of the pooled samples (QCs) are shown in Supplementary
Table 4.
4. Discussion
This is to our knowledge, the largest nontargeted blood
lipidomics study in AD to date. Here, we expanded our
recent work [9], and using univariate and multivariate ap-
proaches, we replicated the associations between six previ-
ously reported blood lipids and AD [9] and reported their
association with brain atrophy. We further identified combi-
nations of lipids that classified AD patients with relatively
good accuracy when tested in both a test and a validation
data set (.70%), and combinations of molecules that
Table 2
List of putatively identified metabolite molecules selected by the six random forest models
Logistic
regression
analysis
m/z
(ionization
mode)
Putative
metabolite
molecule
Present study data set Proitsi et al 2015 data set Meta-analysis
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Clinical AD
diagnosis
882 (2) PC 40:4 1.996 1.35–3.01 6.79E204* NA NA NA NA NA NA
948 (1) TG 57:1 0.514 0.36–0.71 8.09E205* 0.522 0.28–0.92 3.01E202 0.516 0.39–0.69 6.83E206*
856 (1) ChoE/TGy 0.711 0.51–0.99 4.34E202 0.141 0.04–0.43 1.75E203 0.632 0.46–0.87 4.94E203*
866 (1) ChoE/TGy 0.663 0.46–0.94 2.42E202 0.251 0.10–0.52 7.51E204* 0.569 0.41–0.79 7.37E204*
868 (1) ChoE/TGy 0.65 0.47–0.89 7.74E203* 0.218 0.07–0.55 3.15E203 0.591 0.44–0.80 7.16E204*
882 (1) ChoE/TGy 0.57 0.41–0.79 7.99E204* 0.231 0.08–0.53 1.56E203 0.517 0.38–0.71 3.05E205*
894 (1) ChoE/TGy 0.732 0.51–1.04 8.05E202 0.151 0.05–0.38 3.14E204* 0.615 0.44–0.86 4.65E203*
970 (1) ChoE/TGy 0.643 0.47–0.87 4.96E203* 0.362 0.18–0.67 2.56E203 0.58 0.44–0.77 1.27E204*
Linear regression
analysis
Beta 95% CI P value NA NA NA NA NA NA
Hippocampus (right) 919 (1) TG 50:2 0.396 0.20–0.59 7.91E205* NA NA NA NA NA NA
Hippocampus (Left) 943 (1) ChoE/TG 0.320 0.13–0.51 9.97E204* NA NA NA NA NA NA
Entorhinal Cortex
(Right)
367 (1) Sterol 20.201 20.39 to 20.01 3.88E202 NA NA NA NA NA NA
Entorhinal Cortex
(Left)
816 (1) NA 0.218 0.03–0.41 2.47E202 NA NA NA NA NA NA
ROD 771 (1) PC 36:3z 20.412 20.65 to 20.17 9.92E204 NA NA NA NA NA NA
Abbreviations: AD, Alzheimer’s disease; ChoE, cholesteryl ester; CI, confidence interval; m/z, mass-to-charge ratio; OR, odds ratio; PC, phosphatidylcho-
line; ROD, rate of cognitive decline; TG, Triglyceride.
NOTE. The six random forest models were for the clinical AD diagnosis, ROD, hippocampus (R/L), and entorhinal cortex (R/L) phenotypes. The association
of eachmolecule is presented with the respective phenotype (i.e., primary phenotype of association). The association of the six molecules previously reported by
Proitsi et al 2015 with AD is also presented.
*Q value ,0.05.
yFeatures identified by Proitsi et al 2015 and for the Proitsi et al., data set semiquantified values are presented.
zPC 36:3 has m/z 770, and m/z 771 is its C13 isotope. ChoE/TG indicates co-elution of ChoE and TG molecules.
Table 3
Random forest classifier model results (clinical AD diagnosis) for the training data set and predictions on the test data set and the Proitsi et al data set
Model (5% tolerance)
Training data set (N 5 179) Test data set (N 5 98) Validation data set (N 5 75)
Sens. Spec. AUC Acc. Sens. Spec. AUC PPV NPV Acc. Sens. Spec. AUC PPV NPV
Covariates only* 0.72 0.71 0.77 0.56 0.54 0.58 0.56 0.5 0.62 0.6 0.57 0.63 0.6 0.57 0.63
25 featuresy 0.82 0.82 0.87 0.73 0.77 0.69 0.73 0.66 0.79 NA NA NA NA NA NA
24 featuresz 0.81 0.82 0.86 0.74 0.74 0.73 0.74 0.68 0.78 0.71 0.69 0.73 0.71 0.69 0.73
25 featuresy 1 covariates* 0.83 0.83 0.88 0.75 0.79 0.71 0.75 0.68 0.81 NA NA NA NA NA NA
24 featuresz 1 covariates* 0.84 0.82 0.88 0.75 0.79 0.71 0.75 0.68 0.81 0.71 0.69 0.73 0.71 0.69 0.73
25 featuresy 1 6 ChoE/TGx 0.82 0.82 0.87 0.71 0.74 0.67 0.71 0.64 0.77 NA NA NA NA NA NA
24 featuresz 1 6 ChoE/TGx 0.82 0.81 0.87 0.71 0.79 0.66 0.72 0.65 0.80 0.72 0.71 0.73 0.72 0.69 0.74
25 featuresz 1 covariates*
1 6 ChoE/TGx
0.83 0.83 0.88 0.74 0.77 0.71 0.74 0.68 0.80 NA NA NA NA NA NA
24 featuresz 1 covariates*
1 6 ChoE/TGx
0.83 0.82 0.88 0.74 0.79 0.69 0.74 0.67 0.81 0.71 0.69 0.73 0.71 0.69 0.73
Abbreviations: Acc, accuracy; AUC, area under the curve; ChoE, cholesteryl ester; NPV, negative predictive value; PPV, positive predictive value; Sens,
sensitivity; Spec, specificity; TG, triglyceride.
*Age, sex, ε4.
y5% tolerance model including negative ionization molecule.
z5% tolerance model excluding negative ionization molecule.
xSix features identified by Proitsi et al 2015.
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predicted changes in disease progression (R25 0.10 for test
data set) and brain atrophy (R2  0.14 for all test data sets
except for left EC). Although these signatures cannot be
used for diagnostic purposes yet, they suggest important bio-
logical mechanisms associated with AD.
4.1. Identification and role of lipids in AD
We putatively identified two PC molecules; additionally,
ChoEs and triglycerides (TGs) were tentatively annotated
due to chromatographic coelution, and finally, we putatively
annotated a molecule as a sterol. The higher MS-MS sensi-
tivity achieved here enabled the detection of a number of
additional lipids that co-eluted with ChoE; these were anno-
tated as TGs (Table 2).
The association of PCs with AD and cognition has been
extensively described [4,8]. Here, one of the molecules
most strongly associated with AD is a putative PC (PC
40:4), and the top lipid in the ROD model is also a putative
PC (PC 36:3). In contrast to the same species of molecules,
we have previously identified, both PCs are increased in
AD, and PC 36:3 is associated with faster ROD. Although
most studies to date have reported a reduction of PC levels
in AD, an increase in CSF PCs has been observed in AD
compared to control brains [19] and recently in “AD-like” pa-
tients based on their CSFAmyloid-beta42, Tau, and Phospho-
Tau-181 levels [20]. A recent study also reported a parallel
increase of PCs containing saturated and short-chain fatty
acids in serum from AD patients [21]. These suggest deregu-
lation in the biosynthesis, turnover, and acyl chain remodeling
of phospholipids, in accordance with increased phospholipid
breakdown due to PLA2 [21] overactivation.
We have also reported associations with low-chain and
very-low-chain triglycerides (LCTs/VLCTs; fatty acid chain
length .16 carbons). One of the most interesting findings
was that due to the higher MS-MS sensitivity achieved in
this study, we were able to observe putative VLCTs that
were coeluting with ChoEs (Table 2). We have previously re-
ported on the synthesis of ChoEs [9]; briefly, it takes place by
transfer of fatty acids from PC to cholesterol, a reaction cata-
lyzed by lecithin cholesterol acyl transferase in plasma and by
acyl-coenzyme A: cholesterol acyl transferase 1 and 2
(ACAT1 and ACAT2) in other tissues, including the brain.
The association of LCTs/VLCTs with AD is noteworthy.
Although overall TGs are seen as risk factors for many disor-
ders including cardiovascular disease (CVD) and type 2 dia-
betes (T2D), numerous investigations point to the diverse role
of TGs with different chain lengths. It is known for example
that medium-chain triglycerides (MCTs) and LCTs have
different metabolic pathways in digestion and absorption
[22]. Moreover, although LCTs of lower carbon number
and double bond content have been associated with increased
CVD [23] and T2D risk [24], LCTs with higher carbon num-
ber and double bond content, like the ones here, have been
associated with decreased risk of T2D [24], whereas no asso-
ciations between T2D and total triglyceride levels were
observed in the same individuals [24]. Furthermore,
decreased concentration of LCTs and an increased concentra-
tion of VLCTs have been associated with longevity [25].
These findings are particularly interesting as most vegetable
oils are comprised of long-chain fatty acids; however, only
MTCs have to our knowledge been implicated in AD,
although findings are controversial [26]. When we previously
investigated the association of total cholesterol and TGs with
AD in overlapping individuals using Mendelian randomiza-
tion, we found no evidence for an association with AD [27].
Additionally, we observed no difference in serum triglycer-
ides, total cholesterol, LDL cholesterol, and HDL cholesterol
between AD patients and controls for a random subset of
study participants in this study (AD 5 102, controls 5 106)
that had serum lipid measures available for the same visit,
as well as no difference in the frequency of AD patients and
controls who were taking statins. On the other hand, a recent
study reported an overlap between genes involved in elevated
plasma lipid levels and inflammation and the risk for AD [28].
All these highlight the relevance of investigating smaller lipid
fractions as they highlight specific steps in their biosynthesis
and metabolism that may be associated with AD.
Finally, we observed an association between most pheno-
types and a feature of m/z 367. We previously described a
molecule with the same mass and similar retention time to
be reduced in AD [9]. The molecule discovered here was
associated with an increased risk for AD in both data sets
and with reduced brain volume and was included in the
ERC and clinical diagnosis models. We believe this feature
is a fragment and a sterol, specifically an isomer of desmos-
terol. Desmosterol is a precursor of cholesterol and seladin
(DHCR24), which governs the metabolism of desmosterol
Table 4
Random forest regression model results for the training data set and
predictions on the test data set for each AD endophenotype
Phenotype
Model
(5% tolerance)
Train data
set (n 5 93)
Test data
set (n 5 28)
RMSE R2 RMSE R2
Hippocampus
(right)
Covariates only* 0.92 0.28 1.09 0.02
12 featuresy 0.58 0.55 0.9 0.15
Hippocampus
(Left)
Covariates only* 0.89 0.34 1.21 0.01
12 featuresy 0.64 0.59 0.99 0.15
Entorhinal
cortex (right)
Covariates only* 0.95 0.22 1.14 ,0.01
12 features 0.66 0.54 0.92 0.14
Entorhinal
cortex (left)
Covariates only* 1.00 0.22 1.17 ,0.01
12 features 0.77 0.42 1.07 0.01
ROD 10 featuresz 0.93 0.49 1.09 0.10
Abbreviations: RMSE, root mean squared error; ROD, rate of cognitive
decline.
*Age, sex, ε4.
yAge was included in the final model. There was no difference in either
train or test data set performance when age was excluded.
zCovariates were already included in the calculation for the ROD.
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to cholesterol in specific brain areas. Desmosterol has been
shown to inhibit b-secretase cleavage of APP, and the forma-
tion of amyloid-b and lower desmosterol levels has been
found in the plasma and brains of AD patients compared
to controls [29–32].
Although the association of aberrant lipid metabolism in
AD pathogenesis is undisputed [33–35]; at this stage, the
mechanisms by which these changes in lipids might occur in
AD are unclear. One possibility involves AD selective
alterations to circulating lipid metabolism. However, another
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Fig. 2. Heatmap of the univariate associations between features selected during random forest analyses for each phenotype. The color of each box represents the
univariate logistic regression beta coefficient (log[OR]) for clinical diagnosis or the univariate scaled linear regression beta coefficients for the rate of cognitive
decline and brain atrophy, after adjusting for covariates. The stars on each box represent the strength of the association: *P value,.05; **P value,.01; ***P
value,.001; ****P value,.0001; *****P value,.00001. The order of the metabolite molecules on the y-axis is based on a hierarchical clustering using the
metabolites pairwise correlations. XN denotes negative ionization mode feature. Abbreviations: AD-CTL, Clinical AD diagnosis; ROD, rate of cognitive
decline; HIP_L, left hippocampus; HIP_R, right hippocampus; ERC_L, left entorhinal cortex; ERC_R, right entorhinal cortex.
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possibility relates to cellular lipid production. A number of
phospholipids are synthesized within a specialized region of
the endoplasmic reticulum (ER) that is closely associated
with mitochondria, the mitochondria-associated ER mem-
branes (MAM). The close association of MAM to mitochon-
dria facilitates Ca21 and phospholipid exchange between the
two organelles [36–38]. Recent studies have shown that
MAM contacts are damaged in AD [39–42]. Because ER-
mitochondria contacts are required for the synthesis of certain
lipids [36–38], such changes may affect lipid metabolism and
lead to some of the changes described here. Indeed, different
APOE alleles have been shown to influence MAM [43].
4.2. Strengths and limitations
Here, we have used a large well-characterized AD cohort
and a careful and systematic analysis pipeline. Through
bootstrapping, we have reduced over-fitting, and subse-
quently, we validated our results in an unseen data set for
each phenotype and an additional validation data set for clin-
ical AD diagnosis. Our AD diagnostic classifier achieved
88% accuracy on the training data set (summary of 100 boot-
straps) and predicted the test and validation data sets with
.70% accuracy. Our training data set comprised of individ-
uals matched on age and gender. On the other hand, the test
data set consisted primarily by females, and AD patients
were significantly older than controls. Additionally, the vali-
dation data set [9] included AD patients and controls of UK
origin only, older than the individuals of the current data set.
These findings highlight robustness in the model. For the AD
endophenotypes, the Random Forest Regression models had
a very good performance on all training data sets. Although
the performance dropped significantly in the test data sets,
we observed R2 . 0.10 for all phenotypes except for Left
EC (R250.01). The drop in performance can be attributed
to over-fitting of the training data sets and the smaller num-
ber of individuals with ROD/brain atrophy measures. The
poor performance of the Left EC is in agreement with our
univariate analyses that highlighted weaker associations
with the EC for the whole sample; however, it is in contrast
to the overall right-to-left asymmetry in AD [17].
A limitation of this study is that we were not able to deci-
pher the exact fatty acid chain structure of some features.
Owing to the higher MS-MS sensitivity, we observed a num-
ber of putative ChoEs and TGs co-eluting, which is
commonly observed in lipidomics studies due to hundreds
of lipids detected in one analysis; to minimize co-elution
problems, our chromatographic run is 2 hours long using ul-
tra pressure chromatography [11,44].
Additionally, although this is the largest AD lipidomics
study to date, we acknowledge that the sample size is still
modest and further replication is required, especially for
the ROD and brain atrophy phenotypes. Moreover, although
we had information on the ROD, this calculation was based
on the MMSE, which is a crude measure of measurement of
cognition. Furthermore, the present study did not contain an
MCI cohort or information on conversion to MCI/AD, and
therefore, we do not know whether these features are associ-
ated with initiation of AD. This study additionally suffers
from limitations inherent to AD case-control studies, such
as the large number of comorbidities in old age, the possibil-
ity that some of the elderly controls may already carry pa-
thology, and that some of the clinically diagnosed AD may
be pathologically non-AD dementias. Finally, this study
lacks information on BMI and body fat distribution that
could potentially explain some of the differences between
AD patients and controls.
However, through the longitudinal nature of these co-
horts, we know that all the AD patients used for our analysis
maintained the diagnosis of AD as did all controls for at least
3 years from their baseline visit. Additionally, our informa-
tion on disease progression and brain atrophy provide us
with more precise phenotypes that capture different stages
of disease pathology including the early preclinical stages.
Given the good performance of these models, we believe
that enrichment with additional individuals and pathology
information would increase their performance. Finally,
although we did not have BMI information for our cohort,
we observed no difference in statin use or serum lipids be-
tween AD cases and controls.
5. Conclusion
In conclusion, the findings of this study deepen our knowl-
edge of AD disease mechanisms and emphasize the impor-
tance of investigating in detail different lipid fractions in
dementia research. As it is not known whether the observed
changes in lipid levels are causally related to or are just a
marker of changes in lipoprotein dynamics and composition,
studies that address causality are essential, as the success of
targeting specificmolecules and identifying potentially causal
pathways amenable to intervention is predicated on these
molecules being on the causal pathway. Finally, integrating
additional types of biological modalities such as protein,
gene expression, and genotype information may increase
the fit of these models and help us to understand more about
the biological context in which these molecules operate.
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RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using PubMed and reported key publications.
There is a pressing need to identify noninvasive Alz-
heimer’s disease (AD) biomarkers, and blood metab-
olites are promising biomarkers that could aid early
diagnosis and ultimately lead to the development of
more effective interventions. Recent blood metabo-
lomic studies have highlighted the role of lipid com-
pounds in AD. However, most studies are small and
relatively heterogeneous.
2. Interpretation: This study replicated previous associ-
ations between blood lipids and AD and reported
novel associations between blood lipids and clinical
AD diagnosis, the rate of cognitive and brain atrophy.
These findings deepen our knowledge of AD disease
mechanisms and suggest novel targets for future
work.
3. Future directions: Results of this study could be com-
plemented with protein and genetic data. Future
studies should address whether these changes are
causally related to AD or are just a marker of changes
in lipoprotein dynamics and composition.
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